Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug...
Transcript of Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug...
![Page 1: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/1.jpg)
Drug Discovery and Preclinical Development
Neal G Simon Ph DNeal G. Simon, Ph.D.Professor
Department of Biological Sciences
![Page 2: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/2.jpg)
Disclaimer
“Th h h k l d d ’t di t“Those who have knowledge, don’t predict. Those who predict, don’t have knowledge.”
Lao Tzu, 6th Century BC Chinese Poet
![Page 3: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/3.jpg)
Discovery and Preclinical Development
I BackgroundI. Background
II. The R&D Landscape
III I ti d T f tiIII. Innovation and Transformation
IV. The Preclinical Development Process
V. Case Study: Stress-related Affective Disorders
![Page 4: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/4.jpg)
Serendipity or Good Science: Building Opportunity
Hoffman Osterhof
![Page 5: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/5.jpg)
I. Background
![Page 6: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/6.jpg)
Drug Development Process
![Page 7: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/7.jpg)
Biopharmaceutical Drug Development: Attrition
Drug Discovery Pre-Clinical Clinical Trials
FDA Review
Large Scale Manufacturing/ Phase IV
Phase I20 100
Phase III
ubm
itted
ubm
itted
250 Compounds 5 Compounds10,000 Com- 1 FDA
A d
20-100 Volunteers
ase1000-5000 Volunteers
IND
Su
ND
A Su250 Compounds 5 Compounds
pounds
Approved Drug
Phase II100-500
5 years 1.5 years 6 years 2 years 2 years
100 500 Volunteers
Quelle: Burrell Report Biotechnology Industry 2006
![Page 8: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/8.jpg)
Capitalized Cost Estimates per New Molecule
*All R&D costs (basic research and preclinical development) prior to initiation of clinical testing** Based on a 5-year shift and prior growth rates for the preclinical and clinical periods.
DiMasi and Grabowski (2007)
![Page 9: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/9.jpg)
II. The Research & Development Landscapep p
![Page 10: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/10.jpg)
R&D Expenditures and Return on Investment: A Declining Function
Phrma (2005); Tufts CSDD (2005)
![Page 11: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/11.jpg)
R&D Expenditures 1992-2004 and FDA Approvals
Hu et al (2007)
![Page 12: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/12.jpg)
NIH Budget by Area
![Page 13: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/13.jpg)
Pharmaceutical Industry: Diminishing Returns
“That is why the business model is under threat: the ability to devise new molecules through R&D and bring them to market is not keeping up with what’s being lost to genericis not keeping up with what s being lost to generic manufacturers on the other end. This situation requires new thinking, new urgency, new capabilities.”
F d H CEO S h i Pl h 2005Fred Hassan, CEO Schering-Plough, 2005
Saltzmann (2006)
![Page 14: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/14.jpg)
III. Innovation and TransformationIII. Innovation and Transformation
![Page 15: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/15.jpg)
Innovation Models and Transformation
Hu et al (2007)
![Page 16: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/16.jpg)
Innovation Models: In-licensing and Acquisitions
Saltzmann (2006)
![Page 17: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/17.jpg)
Me Too Drugs: Antidepressants
1986 Fluvoxamine (Luvox; Solvay) SSRI
1987 Fluoxetine (Prozac; Lilly) SSRI
1992 Sertraline* (Zoloft; Pfizer) SSRI/NRI
1993 Venlafaxine (Effexor; Wyeth) SSRI/NRI
1996 Buproprion (Wellbutrin; Wyeth) SNRI/DRI1996 Buproprion (Wellbutrin; Wyeth) SNRI/DRI
2002 Escitalopram (Lexapro; Forrest) SSRI
2004 Duloxetine (Cymbalta; Lilly) SSRI/NRI
![Page 18: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/18.jpg)
Personalized Medicine (sort of)
![Page 19: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/19.jpg)
Discovery & Preclinical Development
IV. Discovery and Preclinical Development
![Page 20: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/20.jpg)
Discovery and Preclinical Development
Lead Selection and Drug Candidate Preclinical DrugLead Selection andOptimization (iterative)
Drug CandidateConfirmation
Preclinical DrugCharacterization
ff ?
Regula
Efficacy Assessment: Does it work?
ADME Profiling: How can it be delivered and what does the body do?
atory Subm
Toxicology/Safety Pharmacology Assessment: Is it safe?
ADME Profiling: How can it be delivered and what does the body do? mission t
Pharmaceutics: Is the manufacture viable and controllable?
Toxicology/Safety Pharmacology Assessment: Is it safe? o FDA
Pharmaceutics: Is the manufacture viable and controllable?
Adapted from TetraQ
![Page 21: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/21.jpg)
Stage 1: Lead Selection and Optimization
• Structural CharacterizationImpurity Identification
Essential Pharmaceutics
• Impurity Identification• Solubility assessment• Prototype formulation• Stability testing
Screening Efficacy
• In silico profiling
Early ADME
Off t t
Early Toxicology
• In vitro models• In vivo models• Other
In silico profiling• Develop simple
analytical method • Measure membrane
permeability
• Off target screen• In vitro cytotoxicity• Preliminary AMES • hERG bindingpermeability
• Plasma Stability
Adapted from TetraQ
![Page 22: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/22.jpg)
Stage 2: Drug Candidate Confirmation
Data from Lead Optimization Stage
Preliminary CMC(Chemistry,
Manufacture and Control)
“Benchmark” invivo Models ADME Profiling Preliminary
Toxicology
• Formulation for GLP ToxicologySt bilit t ti
Control)
I i d l
• Optimized analytical method
• Maximum tolerated dose• Stability testing
of active ingredient
• Detailed h i h i l
• In vivo models• Validated
models• Models in other
di
method development
• Basic pharma-cokinetics (PK) & Oral
tolerated dose (MTD)
• Repeat Dose (non-GLP)
• Preliminaryphysicochemical characterization• Impurity
analysis
disease areas & Oral Bioavailability
• Determine metabolism of drug
Preliminary Cardiovascular Safety Pharmacology
drug
Adapted from TetraQ
![Page 23: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/23.jpg)
Stage 3: Preclinical Drug Characteristics
Data from Prior Stages
Comprehensive ADME
Detailed Preclinical CMC
GLP Toxicology Package
• analytical method development
• Comprehensive
• ICH Stability Testing
ICH i it
• acute study• subchronic repeat
dose studypPharmacokinetics
• GLP TK• Comprehensive
identification of
• ICH impurity analysis
•Develop prototype clinical formulation
y• Genotoxicity
Battery• Safety
Pharmacologymetabolites
gy
Regulatory Submission or Presentation to Pharma
Adapted from TetraQ
![Page 24: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/24.jpg)
V. Case Study: Stress-related Affective Disorders
![Page 25: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/25.jpg)
Overview
d l ll l l d f GPCR‐targeted oral small molecule drugs for stress,
mood, and behavior disorders
First compounds: vasopressin receptor antagonists
Somewhere between skunk works, serendipity, and p y
good planning
![Page 26: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/26.jpg)
AVP: Biological Diversity
Invertebrate & VertebratePhysiology
Vertebrate Behavior
fluid regulation
b h d t t b li
communication
l b h i carbohydrate metabolism
thermoregulation
sexual behavior
pair bonding
reproductive function paternal/maternal care
social memory
stress-related disorders
impulsivity/violencep y
![Page 27: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/27.jpg)
Hypothalamic-Pituitary Adrenal Axis
![Page 28: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/28.jpg)
Compound #1
Profile:
• Novel oral vasopressin AVP receptor antagonist
• Initial clinical development for stress‐related affective illness
• Serenic activity established in rodent models
Market:
• $20+ billion World Wide Market
• 35 million people affected by anxiety and depression in US alone
Status:
• Phase I completed
• Phase II in planning
![Page 29: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/29.jpg)
Compound #1: Preclinical Development
I in vitro Biology and PKI. in vitro Biology and PK
II. IND-directed Toxicology and Pharmacologygy gy
III. Behavior and Neuroimaging
* NIMH (MH063663), NIH Roadmap Initiative, NCI
![Page 30: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/30.jpg)
Binding and Function at Human AVP Receptor
A competitive binding assay was conducted in CHO cells transfected with human AVP receptor (left panel) Compound #1 inhibited AVP mediated phosphatidylAVP receptor (left panel). Compound #1 inhibited AVP- mediated phosphatidyl inositol turnover with a Ki value at 0.16 nM (right panel).
I hibiti f H AVP Bi di b Inhibition of AVP Induced IP3 ProductionInhibition of Human AVP Binding by
800
1000
AVP
3000
3500
EC50 = 0 87 nM
400
600
800
IC50 = 0.49 nMKi = 0.30 nM
of B
ound
3 H-A
1500
2000
2500
3000 EC50 = 0.87 nMKi = 0.16 nM
PM o
f3 H-IP
3
-13 -12 -11 -10 -9 -8 -7 -6 -50
200CPM
-13 -12 -11 -10 -9 -8 -7 -6 -50
500
1000CP
Concentration: Log M Concentration: Log M
![Page 31: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/31.jpg)
Compound #1: Selectivity
Receptor Class #1
Tested at vs 64 receptors including 35 GPCRsReceptor Class #1
(% inhibition)Vasopressin 1 80.40%
N t itt l t d 20% t +20%Neurotransmitter related -20% to +20%Steroids -20% to +20%
Ion channels -20% to +20%Second messengers -20% to +20%
Prostaglandins -20% to +20%G th f t /h 20% t +20%Growth factors/hormones -20% to +20%
Brain/gut peptides (not including Vasopressin 1)
-20% to +20%
Enzymes -20% to +20%*-20% to +20% is considered “baseline,” which is defined as “inactive”
![Page 32: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/32.jpg)
Compound #1: IND-Directed Studies
Genetic Safety MammalianGenetic Toxicology
SafetyPharmacology
Mammalian Toxicology
AMES hERG 7-day Repeat Oral AMES
Chromosomal Aberration
hERG
Rat Irwin
7-day Repeat Oral (gavage) in Rats
28-day Repeat Oral Cardiovascular &
Pulmonary Safety in Dogs
(gavage) dose in Rats
7-day DRF in Dogs
28-day Repeat Oral (capsule) dose in Dogs (just completed)
![Page 33: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/33.jpg)
Compound #1: hERG Test for QT Prolongation
Values shown are Inhibition of Current (%) + SEM
Test Compound % Inhibition SEMCompound 1 32.9 1.5Positive Control 76.7 2.8(t f di 60 M)(terfenadine 60 nM)
Conducted by ChanTest, Inc; Covance GLP study 7252-117
Results: IC50 = 1.9 μM indicating low risk of cardiac arrhythmias based on anticipated clinical dosing
![Page 34: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/34.jpg)
Compound #1 Blocks Vasopressin-induced Increases in Blood Pressure
Blood Pressure
20
25
m H
g) Blood Pressure20
25
m H
g)
10
15
ssur
e (m
m
**10
15
ssur
e (m
m
**
5
10
lood
pre
s
**5
10
lood
pre
s
**
0vehicle 0.16 0.4 1 2.5
B0AVP Only 0.16 0.4 1 2.5
Dose (mg/kg)
B
Dose (mg/kg)** p<0.05 vs vehicle
![Page 35: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/35.jpg)
Vasopressin is Linked to Stress-related Disorders
R. Landgraf (2006). Involvement of the vasopressin system in stress-related disorders. CNS & Neurological Disorders – Drug Targets 5, 167-179
Increased synthesis, content, and release of AVP in PVN in HAB and LAB rats under basal conditions
![Page 36: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/36.jpg)
Elevated Vasopressin is Linked to Stress-related Disorders: Rodent Model
AVP in the paraventricular nucleus (PVN) flanking the 3rd ventricle (3V) inAVP in the paraventricular nucleus (PVN) flanking the 3rd ventricle (3V) in HAB (high anxiety) and LAB (low anxiety) mice.
Elevated Plus Maze Forced Swim Test
Bunck et al. (2009)
![Page 37: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/37.jpg)
AVP mRNA in Supraoptic and Paraventricular Nuclei from Depressed and Control Individuals
Meynen et al (2006)
Signal on film in SON and PVNAVP mRNA in PVN and SON in depressed (n=9) and control patients (n=8)
![Page 38: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/38.jpg)
fMRI: Imaging Stress/Arousal in Awake Animals
Piloerection is an index of autonomic activationPiloerection is an index of autonomic activation
![Page 39: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/39.jpg)
Compound #1 Blocks Stress & Arousal: Composite View
Mate/Intruder + Compound #1
Imaging on awake rats
![Page 40: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/40.jpg)
Compound #1: Blockade of Stress/Arousal in Major Brain Regions
er
Amygdala Cortex Hippocampus Thalamus
& In
trud
eM
ate
ent
Trea
tm
![Page 41: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/41.jpg)
Activation of Olfactory and Reward Pathways in the Presence of Compound #1 but not Fluoxetine
![Page 42: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/42.jpg)
Serendipity or Good Science: Building Opportunity
Hoffman Osterhof
![Page 43: Drug Discovery and Preclinical Development - Lehighinbios21/PDF/Fall2009/Simon09042009.pdf · Drug Discovery and Preclinical Development Neal G Simon Ph DNeal G. Simon, ... (basic](https://reader033.fdocuments.in/reader033/viewer/2022052607/5a74c8857f8b9aa3688bf462/html5/thumbnails/43.jpg)
Thanks for Your Time and Attention